Safety & Side Effects

GI tolerability, serious adverse events, thyroid warnings, and contraindications

The Safety Profile

More receptor targets means more potential side effects. Retatrutide's Phase 2 data showed a familiar GI side effect profile -- nausea, diarrhea, vomiting -- that was largely manageable with slow titration. But three-receptor agonism also raises unique monitoring questions around thyroid C-cells, pancreatitis, and hepatic effects. This unit gives you the complete safety picture from published data.

Explore the Safety Heatmap

Compare adverse event rates across all four dose tiers to see how side effects scale with dosage and how titration affects tolerability.

interactive safety heatmap

Knowledge Check

Test what you've learned about retatrutide's safety profile.

Practice Exercises

Reinforce your understanding.